Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages.
Dipyridamole (DPM) is commonly used as a coronary vasodilator and inhibitor of platelet aggregation in the treatment of cardiovascular diseases. We report here that DPM potentiates the inhibitory effects of 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine against human immunodeficiency virus type 1 (HIV-1) in human monocyte-macrophages. At the same concentrations, DPM does not potentiate the toxic effects of AZT on these cells or on human bone marrow (granulocyte-monocyte) progenitor cells. Since monocyte-macrophage lineage cells appear to be the major reservoir for HIV-1 in vivo, these findings suggest the possibility of using DPM or its analogues in combination chemotherapy of HIV infections.
Szebeni
J
J
Theoretical Immunology Section, National Cancer Institute, Bethesda, MD 20892.
Wahl
S M
SM
Popovic
M
M
Wahl
L M
LM
Gartner
S
S
Fine
R L
RL
Skaleric
U
U
Friedmann
R M
RM
Weinstein
J N
JN
D000998:Antiviral Agents; D001692:Biological Transport; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D002470:Cell Survival / Q000187:drug effects; D015224:Dideoxynucleosides / Q000378:metabolism; D004176:Dipyridamole / Q000008:administration & dosage*; D004357:Drug Synergism; D006678:HIV / Q000187:drug effects* / Q000254:growth & development; D006801:Humans; D066298:In Vitro Techniques; D007370:Interferon Type I / Q000096:biosynthesis; D008264:Macrophages / Q000187:drug effects; D009000:Monocytes / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects*; D016047:Zalcitabine; D015215:Zidovudine / Q000008:administration & dosage*
D000998:Antiviral Agents; D015224:Dideoxynucleosides; D007370:Interferon Type I; D015215:Zidovudine; D004176:Dipyridamole; D016047:Zalcitabine